Earnings summaries and quarterly performance for CRESCENT BIOPHARMA.
Executive leadership at CRESCENT BIOPHARMA.
Board of directors at CRESCENT BIOPHARMA.
Research analysts covering CRESCENT BIOPHARMA.
Recent press releases and 8-K filings for CBIO.
Crescent Biopharma Announces Strategic Partnership, Private Placement, and Pipeline Updates
CBIO
M&A
New Projects/Investments
- Crescent Biopharma announced an exclusive partnership with Kelun-Biotech to develop and commercialize oncology therapeutics, including CR-001 (a PD-1 x VEGF bispecific antibody) and SKB105 (CR-003, an integrin beta-6-directed ADC). Under the agreement, Crescent gains exclusive rights to SKB105 in the US, Europe, and other markets outside Greater China, while Kelun-Biotech receives exclusive rights to CR-001 in Greater China.
- The company also announced a $185 million private placement, expected to close around December 8, 2025, which is anticipated to provide a cash runway into 2028 and support key clinical data readouts beginning in Q1 2027.
- CR-001, CR-002, and CR-003 (SKB105) are on track to enter the clinic in 2026. Specifically, Phase 1/2 trials for CR-001 and CR-003 are expected to initiate in Q1 2026, with CR-002 following in H2 2026.
- Initial clinical data from the first CR-001 x ADC combination trial is expected by year-end 2026, and proof-of-concept data for CR-001 and CR-003 monotherapies are anticipated in Q1 2027.
- Under the SKB105 License Agreement, Crescent OpCo has agreed to pay Kelun-Biotech $80.0 million within 30 days of signing, up to $345.0 million in development milestone payments, and up to $902.5 million in sales-based milestone payments, in addition to tiered royalties.
20 hours ago
Crescent Biopharma Reports Q3 2025 Financial Results and Pipeline Progress
CBIO
Earnings
Guidance Update
New Projects/Investments
- Crescent Biopharma reported a net loss of $24.6 million, or $1.27 per basic and diluted share, for the three months ended September 30, 2025.
- As of September 30, 2025, the company's cash position was $133.3 million, which is anticipated to fund operations through 2027.
- The Investigational New Drug (IND) application for CR-001 is on track for submission in the fourth quarter of 2025, with a global Phase 1 trial expected to commence in the first quarter of 2026 and initial clinical data anticipated in the second half of 2026.
- Crescent also expects to submit an IND application for CR-002 in mid-2026.
Nov 6, 2025, 12:30 PM
Quarterly earnings call transcripts for CRESCENT BIOPHARMA.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track CRESCENT BIOPHARMA's earnings for you
Get instant analysis when filings drop